Treatment of Hepatitis B in HIV-Positive Patients
All HIV-positive patients with chronic hepatitis B (HBsAg-positive) should receive anti-HBV treatment as part of their antiretroviral therapy, regardless of ALT or HBV DNA levels, using tenofovir (TDF or TAF) plus either emtricitabine or lamivudine. 1
Core Treatment Approach
The management of HBV in HIV coinfection differs fundamentally from HBV monoinfection because treatment must address both viruses simultaneously. The most recent EASL 2025 guidelines provide the clearest directive: treat all HBsAg-positive individuals living with HIV, irrespective of viral load or liver enzyme levels 1. This represents a significant departure from older approaches that used treatment thresholds.
Preferred Regimen
The antiretroviral regimen must contain tenofovir (either TDF or TAF) combined with either lamivudine (150 mg twice daily) or emtricitabine 2, 1, 3. This combination provides:
- Dual activity against both HIV and HBV
- Lower resistance rates compared to lamivudine monotherapy
- Improved long-term outcomes including reduced progression to cirrhosis and hepatocellular carcinoma
The 2008 U.S. treatment algorithm specifically recommends tenofovir plus emtricitabine (available as Truvada) as part of a fully suppressive antiretroviral regimen 4. For treatment-naive patients requiring therapy for both viruses, efavirenz/emtricitabine/tenofovir (Atripla) represents a reasonable single-tablet option 4.
Critical Dosing Distinction
A crucial caveat: The lamivudine dose differs between HBV monoinfection and HIV coinfection. For HIV/HBV coinfected patients, lamivudine must be dosed at 150 mg twice daily (the HIV dose), not the 100 mg daily used for HBV monoinfection 2. This higher dose is necessary for adequate HIV suppression.
Alternative Scenarios
When Tenofovir Cannot Be Used
If tenofovir is contraindicated (e.g., significant renal dysfunction), consider an alternative HIV regimen combined with entecavir 4. However, entecavir should never be used without a fully suppressive HIV regimen because it has partial anti-HIV activity that could select for HIV resistance 4.
Patients Not Requiring HIV Treatment
For the rare HIV-positive patient with chronic HBV who does not yet meet criteria for HIV treatment, options include:
- Pegylated interferon (if young, immunocompetent, low HBV DNA, high ALT, and no cirrhosis) 4
- Adefovir 10 mg daily 4
- Entecavir 4
However, pegylated interferon has limited data in HIV coinfection and shows decreased response compared to HBV monoinfection 5, 6. The advantage of interferons is that they don't select for drug-resistant HIV 4.
Agents to Avoid
Never use lamivudine or emtricitabine as the sole anti-HBV agent in HIV/HBV coinfected patients 4, 7, 8. These drugs have:
- High rates of HBV resistance (up to 44% with lamivudine monotherapy)
- Cross-resistance with other antivirals
- Risk of selecting vaccine escape mutants
- Potential for severe hepatitis flares upon discontinuation
Lamivudine monotherapy should only be considered in patients with very low HBV DNA levels, and even then, it's suboptimal 7, 8.
Managing Lamivudine Resistance
For patients who develop lamivudine-resistant HBV, add tenofovir to the regimen 4, 5. The combination of tenofovir plus lamivudine (or emtricitabine) may reduce the rate of developing tenofovir-resistant HBV 4.
Treatment Duration and Monitoring
Anti-HBV therapy should never be discontinued in HIV/HBV coinfection due to the high risk of HBV reactivation and potentially fatal hepatitis flares 1. This is lifelong therapy.
Monitor treatment response according to standard HBV guidelines, but account for the HIV coinfection status 1. Long-term tenofovir therapy can lead to significant declines in HBsAg levels 3.
Special Considerations
Cirrhosis
- Compensated cirrhosis: Use tenofovir-based regimen; avoid interferon due to risk of hepatic decompensation 2
- Decompensated cirrhosis: Tenofovir-based regimen is essential; interferon is absolutely contraindicated 2, 1
Renal Function
When using tenofovir (particularly TDF), monitor renal function closely. TAF may have a better renal safety profile than TDF, though both are effective 1.
Hepatocellular Carcinoma
HIV/HBV coinfected patients have increased HCC risk. If HCC develops, continue antiviral therapy regardless of HBV DNA levels 1. Some evidence suggests TDF may be superior to entecavir for tertiary HCC prophylaxis after curative treatment, though this is based primarily on Asian cohorts 1.
Key Pitfalls to Avoid
- Never start lamivudine, emtricitabine, or entecavir without full HIV suppression - this risks HIV resistance
- Never use the HBV monoinfection dose of lamivudine (100 mg daily) in coinfected patients
- Never stop anti-HBV therapy once started in HIV coinfection
- Never use interferon in decompensated cirrhosis
- Don't delay treatment waiting for HBV DNA results in patients with decompensated disease